XML 34 R23.htm IDEA: XBRL DOCUMENT
v3.21.2

Stock-Based Compensation (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2021
Share-based Payment Arrangement [Abstract] |
Schedule of Stock Options Issued and Outstanding Activities | Stock options issued and outstanding under the Lucid Diagnostics Inc. 2018 Equity Plan for the period indicated is as follows: Schedule of Stock Options Issued and Outstanding Activities
|  | Number Stock Options |  |  | Weighted Average Exercise Price |  |  | Remaining Contractual Term (Years) |
Outstanding stock options at December 31, 2020 |  |  | 1,399,243 |  |  | $ | 0.61 |  |  |  | 8.0 |
Granted(1) |  |  | — |  |  | $ | — |  |  |  |  |
Exercised |  |  | — |  |  | $ | — |  |  |  |  |
Forfeited |  |  | — |  |  | $ | — |  |  |  |  |
Outstanding stock options at September 30, 2021 |  |  | 1,399,243 |  |  | $ | 0.61 |  |  |  | 7.5 |
Vested and exercisable stock options at September 30, 2021 |  |  | 1,120,526 |  |  | $ | 0.57 |  |  |  | 7.4 |
(1) | Stock options granted under the Lucid Diagnostics Inc. 2018 Equity Plan generally vest ratably over twelve quarters, with the vesting commencing with the grant date quarter, and have a ten-year contractual term from date-of-grant.
Schedule of Stock-Based Compensation Expense | The stock-based compensation expense recognized by the Company for both the Lucid Diagnostics Inc. 2018 Equity Plan and the PAVmed Inc. 2014 Equity Plan, for the periods indicated, was as follows: Schedule of Stock-Based Compensation Expense
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2021 |  |  | 2020 |  |  | 2021 |  |  | 2020 |
Lucid Diagnostics Inc 2018 Equity Plan – general and administrative expense |  | $ | 2,694,882 |  |  | $ | — |  |  | $ | 5,988,299 |  |  | $ | — |
Lucid Diagnostics Inc 2018 Equity Plan – research and development expenses |  |  | 21,864 |  |  |  | 13,114 |  |  |  | 57,156 |  |  |  | 39,344 |
PAVmed Inc 2014 Equity Plan - research and development expenses |  |  | 56,456 |  |  |  | 3,251 |  |  |  | 111,084 |  |  |  | 9,750 |
Total stock-based compensation expense – recognized by Lucid Diagnostics Inc |  | $ | 2,772,202 |  |  | $ | 16,365 |  |  | $ | 6,156,539 |  |  | $ | 49,094 |
Schedule of Unrecognized Compensation Expense and Weighted Average Remaining Service Period | As of September 30, 2021, unrecognized stock-based compensation expense and weighted average remaining requisite service period with respect to stock options granted under each of the Lucid Diagnostics Inc. 2018 Equity Plan and the PAVmed Inc. 2014 Equity Plan, as discussed above, is as follows: Schedule of Unrecognized Compensation Expense and Weighted Average Remaining Service Period
|  | Unrecognized Stock-Based Compensation Expense |  |  | Weighted Average Remaining Service Period |
Lucid Diagnostics Inc. 2018 Equity Plan |  |  |  |  |  |  |  |
Stock Options |  | $ | 14,970 |  |  |  | 0.3 years |
Restricted Stock Awards |  | $ | 17,491,130 |  |  |  | 1.5 years |
PAVmed Inc. 2014 Equity Plan |  |  |  |  |  |  |  |
Stock Options |  | $ | 520,665 |  |  |  | 2.5 years |

X
- References No definition available. + Details
Name: | LUCD_ScheduleOfUnrecognizedCompensationExpenseAndWeightedAverageRemainingServicePeriodTableTextBlock
Namespace Prefix: | LUCD_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details
Name: | us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901 + Details
Name: | us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration